Aprogen Pharmaceuticals Inc Asset Resilience Ratio
Aprogen Pharmaceuticals Inc asset resilience ratio. Aprogen Pharmaceuticals Inc (003060) has an Asset Resilience Ratio of 4.32% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Aprogen Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aprogen Pharmaceuticals Inc (2009–2024)
Asset resilience ratio of Aprogen Pharmaceuticals Inc from 2009 to 2024. This chart shows how Aprogen Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Aprogen Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aprogen Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Aprogen Pharmaceuticals Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩26.07 Billion | 4.32% |
| Total Liquid Assets | ₩26.07 Billion | 4.32% |
Asset Resilience Insights
- Limited Liquidity: Aprogen Pharmaceuticals Inc maintains only 4.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aprogen Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aprogen Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Aprogen Pharmaceuticals Inc Asset Resilience Ratio by Year (2009–2024)
Aprogen Pharmaceuticals Inc asset resilience ratio by year from 2009 to 2024. The table below shows the annual Asset Resilience Ratio data for Aprogen Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.40% | ₩26.01 Billion ≈ $17.63 Million |
₩590.98 Billion ≈ $400.50 Million |
-6.63pp |
| 2022-12-31 | 11.03% | ₩75.46 Billion ≈ $51.14 Million |
₩684.14 Billion ≈ $463.63 Million |
-3.59pp |
| 2021-12-31 | 14.62% | ₩89.86 Billion ≈ $60.90 Million |
₩614.62 Billion ≈ $416.52 Million |
-8.18pp |
| 2020-12-31 | 22.80% | ₩140.28 Billion ≈ $95.07 Million |
₩615.31 Billion ≈ $416.99 Million |
-15.31pp |
| 2019-12-31 | 38.11% | ₩139.21 Billion ≈ $94.34 Million |
₩365.28 Billion ≈ $247.55 Million |
+19.30pp |
| 2018-12-31 | 18.81% | ₩40.83 Billion ≈ $27.67 Million |
₩217.06 Billion ≈ $147.10 Million |
+12.74pp |
| 2017-12-31 | 6.07% | ₩9.61 Billion ≈ $6.51 Million |
₩158.27 Billion ≈ $107.26 Million |
-18.88pp |
| 2016-12-31 | 24.95% | ₩32.11 Billion ≈ $21.76 Million |
₩128.69 Billion ≈ $87.21 Million |
+24.88pp |
| 2015-12-31 | 0.07% | ₩60.00 Million ≈ $40.66K |
₩85.22 Billion ≈ $57.75 Million |
-20.81pp |
| 2014-12-31 | 20.88% | ₩17.71 Billion ≈ $12.00 Million |
₩84.83 Billion ≈ $57.49 Million |
+15.70pp |
| 2013-12-31 | 5.19% | ₩4.06 Billion ≈ $2.75 Million |
₩78.26 Billion ≈ $53.04 Million |
+2.78pp |
| 2012-12-31 | 2.41% | ₩2.24 Billion ≈ $1.52 Million |
₩93.08 Billion ≈ $63.08 Million |
-2.00pp |
| 2011-12-31 | 4.41% | ₩5.13 Billion ≈ $3.48 Million |
₩116.33 Billion ≈ $78.84 Million |
+1.36pp |
| 2010-12-31 | 3.05% | ₩2.40 Billion ≈ $1.63 Million |
₩78.70 Billion ≈ $53.33 Million |
+0.27pp |
| 2010-09-30 | 2.78% | ₩1.88 Billion ≈ $1.27 Million |
₩67.64 Billion ≈ $45.84 Million |
+2.10pp |
| 2009-12-31 | 0.68% | ₩402.20 Million ≈ $272.57K |
₩59.07 Billion ≈ $40.03 Million |
-- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.